Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Genmab ( (GMAB) ).
Genmab A/S announced its Annual General Meeting scheduled for March 12, 2025, in Copenhagen, where key agenda items include the adoption of the audited Annual Report 2024, re-election of board members, and proposed amendments to the Remuneration Policy. The meeting will address the company’s profit distribution and board nominations, with a focus on aligning remuneration practices with shareholder interests, ensuring internationally competitive compensation packages.
More about Genmab
Genmab is an international biotechnology company focused on developing innovative antibody therapeutics to improve the lives of patients. Established in 1999 and headquartered in Copenhagen, Denmark, it has a global presence and aims to transform cancer and serious disease treatments by 2030 with its proprietary technologies such as bispecific T-cell engagers and antibody-drug conjugates.
YTD Price Performance: -6.24%
Average Trading Volume: 1,344,418
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $12.16B
Learn more about GMAB stock on TipRanks’ Stock Analysis page.
